OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Oncology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	753
JAMA Oncology	447
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	369
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	312
Error in Text	296
Errors in Key Points and Abstract	291
Stargazers	275
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	270
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	259
Overall Survival in the CAIRO5 Clinical Trial	238
Piercing the Fog	227
The Multidisciplinary Cancer Conference	205
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	199
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	199
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	185
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	182
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	176
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	172
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	156
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	153
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	151
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	150
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	148
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	143
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	139

Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	139
Her Defiance	139
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	137
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	131
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	130
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	129
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	128
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	125
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	122
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	122
The SOUND Randomized Clinical Trial Results	113
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	113
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	107
Results of the TARGET-TP Randomized Clinical Trial	107
An Atypical Rash on the Chest	100
Immunotherapy Before Chemoradiotherapy—More Is Better?	99
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	98
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	96
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	96
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	95
Rethinking End Points in Modern Oncology Trials—Beyond the P Value	94
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	92
Shifting Toward Precision Oncology in SCLC Treatment	91
JAMA Oncology	91
Trauma	91
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	90
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	89
Coding Errors in Study of Eligibility for Lung Cancer Screening	89
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer	86
Error in Text	86
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	84
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	84
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	84
JAMA Oncology	81
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	81
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	80
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	80
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	80
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	80
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	80
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	79
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	78
Challenges in Interpreting MELATORCH Trial Outcomes—Reply	78
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	77
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	77
Clinical Trial Diversity—Will We Know It When We See It?	75
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	75
Variability in COVID-19 Vaccine Response Among People With Cancer	75
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	74
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	74